08H
8-chloro-1-methyl-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine
Find entries where: 08H
is present as a standalone ligand in 2 entries
Chemical Component Summary | |
---|---|
Name | 8-chloro-1-methyl-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine |
Synonyms | ALPRAZOLAM |
Identifiers | 8-chloranyl-1-methyl-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine |
Formula | C17 H13 Cl N4 |
Molecular Weight | 308.76 |
Type | NON-POLYMER |
Isomeric SMILES | Cc1nnc2n1-c3ccc(cc3C(=NC2)c4ccccc4)Cl |
InChI | InChI=1S/C17H13ClN4/c1-11-20-21-16-10-19-17(12-5-3-2-4-6-12)14-9-13(18)7-8-15(14)22(11)16/h2-9H,10H2,1H3 |
InChIKey | VREFGVBLTWBCJP-UHFFFAOYSA-N |
Chemical Details | |
---|---|
Formal Charge | 0 |
Atom Count | 35 |
Chiral Atom Count | 0 |
Bond Count | 38 |
Aromatic Bond Count | 17 |
Drug Info: DrugBank
DrugBank ID | DB00404 |
---|---|
Name | Alprazolam |
Groups |
|
Description | Alprazolam is a triazolobenzodiazepine indicated for the treatment of anxiety and panic disorders.[L34783, L34788] It is mainly metabolized by CYP3As and so is contraindicated with CYP3A inhibitors like ketoconazole and itraconazole.[L34783, L34788] Benzodiazepine treatment should be stopped gradually by tapering down a patient's dose to avoid withdrawal symptoms.[A18125] Alprazolam's adverse effects are generally related to the sedation it can cause.[A18125] Alprazolam has been mixed with alcohol as a drug of abuse to potentiate the sedative effects of the drug which may lead to coma and death.[A18125] Alprazolam was given FDA approval on October 16, 1981.[L6148] |
Synonyms |
|
Brand Names |
|
Indication | Alprazolam is indicated for the acute treatment of generalized anxiety disorder in adults.[L34783] Alprazolam is also indicated, either as a standard or extended-release formulation, for the treatment of panic disorder with or without agoraphobia in adults.[L34783, L34788] Alprazolam may also be prescribed off-label for insomnia, premenstrual syndrome, and depression.[A177973] |
Categories |
|
ATC-Code | N05BA12 |
CAS number | 28981-97-7 |
Drug Targets
Name | Target Sequence | Pharmacological Action | Actions |
---|---|---|---|
GABA(A) Receptor | MRKSPGLSDCLWAWILLLSTLTGRSYGQPSLQDELKDNTTVFTRILDRLL... | unknown | positive allosteric modulator |
GABA(A) Receptor Benzodiazepine Binding Site | MRKSPGLSDCLWAWILLLSTLTGRSYGQPSLQDELKDNTTVFTRILDRLL... | unknown | ligand |
Cytochrome P450 3A7 | MDLIPNLAVETWLLLAVSLILLYLYGTRTHGLFKKLGIPGPTPLPFLGNA... | unknown | substrate |
Cytochrome P450 3A4 | MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNI... | unknown | substrate |
Cytochrome P450 2C9 | MDSLVVLVLCLSCLLLLSLWRQSSGRGKLPPGPTPLPVIGNILQIGIKDI... | unknown | substrate |
View More |
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison
T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS.
Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682
Related Resource References
Resource Name | Reference |
---|---|
CCDC/CSD | CAKYOE |
PubChem | 2118 |
ChEBI | CHEBI:2611 |
ChEMBL | CHEMBL661 |
Pharos | CHEMBL661 |